Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.45 |
| ▸ | KIT | P10721 | 9/20 | 0.43 |
| ▸ | BRAF | P15056 | 9/20 | 0.43 |
| ▸ | FLT1 | P17948 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ASPH | Q12797 | 1/20 | 0.43 |
| ▸ | RIOX2 | Q8IUF8 | 1/20 | 0.43 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | PYGL | P06737 | 2/20 | 0.40 |
| ▸ | PYGM | P11217 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4035005 | 0.89 | KDR (0.45) | KDRKITBRAFFLT1KDM4E | |
| SCHEMBL4037145 | 0.89 | KDM4E (0.48) | KDRFLT1KDM4EASPHRIOX2 | |
| SCHEMBL4037293 | 0.88 | KIT (0.51) | KDRKITBRAFFLT1KDM4E | |
| SCHEMBL4037276 | 0.86 | KDR (0.43) | KDRKITBRAFFLT1TP53 | |
| SCHEMBL4037147 | 0.83 | KDR (0.43) | KDRFLT1KDM4EASPHRIOX2 | |
| SCHEMBL6542888 | 0.83 | KDR (0.43) | KDRFLT1KDM4EASPHRIOX2 | |
| SCHEMBL4037432 | 0.82 | KDR (0.44) | KDRFLT1KDM4EASPHRIOX2 | |
| SCHEMBL4032277 | 0.80 | KDR (0.42) | KDRFLT1KDM4ETP53MAPT | |
| SCHEMBL4038209 | 0.79 | NPC1 (0.50) | KITBRAFKDM4ETP53MAPT | |
| SCHEMBL3867635 | 0.78 | KIT (0.52) | KDRKITBRAFFLT1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392680-B1 | SELECTIVE ANTHRANILAMIDE PYRIDINE AMIDES AS INHIBITORS OF VEGFR-2 AND VEGFR-3 | BAYER SCHERING PHARMA AG (DE) | 2009-07-22 | — | — | EP | disclosed |
| US-20040254185-A1 | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254185-A1 | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 | FLT4, KDR, FLT1 | KDR 2/4885KIT 34/4885BRAF 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.